Compare IVR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | OCS |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.0M | 732.4M |
| IPO Year | 2008 | 2022 |
| Metric | IVR | OCS |
|---|---|---|
| Price | $5.54 | $8.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $8.17 | ★ $36.73 |
| AVG Volume (30 Days) | ★ 3.4M | 312.2K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 26.09% | N/A |
| EPS Growth | ★ 103.08 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.36 | N/A |
| Revenue Next Year | $8.03 | $365.20 |
| P/E Ratio | $55.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.22 | $7.11 |
| 52 Week High | $9.50 | $34.48 |
| Indicator | IVR | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 38.73 |
| Support Level | N/A | $7.11 |
| Resistance Level | $5.77 | $13.49 |
| Average True Range (ATR) | 0.17 | 0.46 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 55.86 | 52.03 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.